Table 1 Patient demographics

Age in years

51 (IQR 33–60)

Male gender

9 (53%)

Body mass index (kg/m²)

30.8 ± 1.8

History of smoking

6 (35%)

Co-morbid chronic obstructive pulmonary disease

2 (12%)

FEV1^† (% predicted)

67.3 ± 4.6

FVC^†† (% predicted)

90.8 ± 3.4

FEV1/FVC

60.9 ± 2.3

Taking high dose inhaled corticosteroid therapy

13 (76%)

Taking an additional controller agent

16 (94%)

Taking omalizumab therapy

3 (18%)

Taking daily systemic corticosteroid therapy

4 (24%)